DARMSTADT, Germany–(BUSINESS WIRE)–Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced its entry into a definitive agreement to acquire Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company headquartered in London, UK, focused on pioneering the design and development of siRNA (short interfering RNA) therapies in areas of high unmet need. The purchase price of $20 per ADS in cash, with each ADS representing three ordinary sh

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.